Scorpion Therapeutics was named as one of the 2021 Endpoints 11, a group of the most promising up-and-coming private biotechnology companies.
Scorpion Therapeutics was named as one of the 2021 Endpoints 11, a group of the most promising up-and-coming private biotechnology companies.